FDA Approves Label Addition for PDE-5 Inhibitor

The FDA approved an addition to the product label for the phosphodiesterase-type-5 inhibitor tadalafil (Cialis) to include its use in combination with finasteride (Proscar). This approval was based on evidence supporting the combined use of these medications, although the document did not specify the details of the study or the number of participants involved. The combination was intended to enhance treatment options, potentially benefiting patients with conditions that both medications address.